# A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

> **NCT04667117** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Quadrivalent influenza vaccine
- **DRUG:** Ofatumumab
- **DRUG:** iDMT

## Key facts

- **NCT ID:** NCT04667117
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-14
- **Primary completion:** 2023-07-06
- **Final completion:** 2023-07-06
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04667117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04667117, "A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04667117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*